

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AK MEDICAL HOLDINGS LIMITED**

**愛康醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1789)**

**VOLUNTARY ANNOUNCEMENT  
CERTIFICATION BY NMPA**

This announcement is made by AK Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep its shareholders and potential investors informed of the latest business development of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company obtained the certification for the dental implant system Class III medical devices approved by the National Medical Products Administration (“**NMPA**”) of the People’s Republic of China (the “**PRC**”) on 3 February 2023.

The product consists of dental implants and dental implants accessories; the dental implants are available in standard and tapered versions and are made of pure titanium TA4 in accordance with GB/T13810 or ISO5832-2, with its surface being treated by sandblasting and acid etching treatment.

Prior to this, in July 2022, the Group obtained the certification for Class III medical devices for bone filling biomaterials for maxillofacial surgery. The approval of these two products marked the Group’s entry into the field of oral and maxillofacial prosthetics. In the future, the Group will draw on its successful experience in orthopaedics and rely on its team of dental experts to focus on new technologies and materials and provide new solutions for dental implants.

By Order of the Board  
**AK Medical Holdings Limited**  
**Li Zhijiang**  
*Chairman*

Beijing, 8 February 2023

*As at the date of this announcement, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Dr. Wang David Guowei as non-executive Director, and Mr. Kong Chi Mo, Dr. Li Shu Wing David and Mr. Eric Wang as independent non-executive Directors.*